Bajaj Healthcare FY26 revenue rises 12.6% to Rs 6,110 million

Strong export-led growth and improved profitability as the company focuses on CNS drug development and global regulatory footprint

HRV Pharma & SMS LifeSciences form strategic partnership for orphan and niche APIs

HRV Pharma and MetroChem forge CDMO alliance to fast-track NCE-1 API development

Both companies will jointly execute development and scale-up of multiple strategic APIs, including late-stage NCE-1 opportunities

Lupin Q2 FY23 revenue up 3.9%; Profit down 71%

With the recent sales force expansion and new product launches, we expect to be back to above-market growth

Alembic Pharmaceuticals Q3 FY23 revenue up 19% to Rs. 1,509 Cr

Net sales for 9M FY23 up 9% to Rs. 4,246 crore and net profit for 9M FY23 at Rs. 189 crore

Lupin Q2 FY2023 revenue remains flat

Investment in R&D was Rs. 337.6 crore (8.3% of sales) for Q2 FY2023 as compared to Rs. 330 crore (8.2% of sales) for Q2 FY2022.

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market